Profile

Procarta Biosystems

Procarta Biosystems is a spin-out from one of Europe’s leading microbiology departments at the John Innes Centre. The company, formed in early 2008, is investigating a novel approach to counter antibiotic resistance and defeat infectious diseases using a DNA decoy technique, which aims to restore antibiotic efficacy against resistant superdrugs, such as methicillin-resistent Staphylococcus aureus (MRSA) and vancomycin-resistant Entercoccus (VRE).

Accessing the skills in the John Innes Centre, Procarta is also able to offer a contract research service creating and improving Streptomyces strains for heterologous production.

Status current

Associated Fund UK Innovation & Science Seed Fund

Sector Medical / Biotechnology

Website www.procartabio.com

Associated Team Members

Relevant News

Procarta receives carb-x award of up to $9.2 million

  FOR DEVELOPMENT OF NEW CLASS OF ANTIBIOTICS TO COMBAT LIFE-THREATENING DRUG-RESISTANT PATHOGENS Stevenage, UK,…

read more

More Companies in Medical / Biotechnology